Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma : A Multicenter, Retrospective Cohort Study (HGCSG2101)

Harada, Kazuaki; Yamamura, Takahiro; Muto, Osamu et al.

Journal of clinical medicine, 2023, 12(4), 1596

Permalink : https://hdl.handle.net/2115/89269

このアイテムのアクセス数:299件（2026-03-13 20:43 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
https://doi.org/10.3390/jcm12041596     11

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
metadata only access
URI
https://hdl.handle.net/2115/89269
タイトル
Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma : A Multicenter, Retrospective Cohort Study (HGCSG2101)
著者
Harada, Kazuaki ; Yamamura, Takahiro ; Muto, Osamu ; Nakamura, Michio ; Sogabe, Susumu ; Sawada, Kentaro ; Nakano, Shintaro ; Yagisawa, Masataka ; Muranaka, Tetsuhito ; Dazai, Masayoshi ; Tateyama, Miki ; Kobayashi, Yoshimitsu ; Kato, Sosuke ; Hatanaka, Kazuteru ; Kawamoto, Yasuyuki ; Yuki, Satoshi ; Sakata, Yuh ; Sakamoto, Naoya ; Komatsu, Yoshito
著者名
Harada, Kazuaki
著者名
Yamamura, Takahiro
著者名
Muto, Osamu
著者名
Nakamura, Michio
著者名
Sogabe, Susumu
著者名
Sawada, Kentaro
著者名
Nakano, Shintaro
著者名
Yagisawa, Masataka
著者名
Muranaka, Tetsuhito
著者名
Dazai, Masayoshi
著者名
Tateyama, Miki
著者名
Kobayashi, Yoshimitsu
著者名
Kato, Sosuke
著者名
Hatanaka, Kazuteru
著者名
Kawamoto, Yasuyuki
著者名
Yuki, Satoshi
著者名
Sakata, Yuh
著者名
Sakamoto, Naoya
e-Rad_Researcher
60333598
著者名
Komatsu, Yoshito
言語
英語
キーワード
pancreatic cancer
nanoliposomal irinotecan
nal-IRI
irinotecan
発行日
2023-02
出版者
MDPI
収録物名
Journal of clinical medicine
巻(号)
12(4)
ページ
1596
抄録
The effects of UGT1A1 gene polymorphisms or prior irinotecan treatment on treatment outcomes of nanoliposomal-irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with unresectable pancreatic ductal adenocarcinoma (PDAC) are not established. This multicenter, retrospective cohort study compared treatment outcomes in patients with UGT1A1*1/*1 and those with UGT1A1*1/*6 or *1/*28 genotypes. We also analyzed the impact of prior irinotecan treatment on survival outcomes in 54 patients treated with nal-IRI+5-FU/LV. Comparable effectiveness was found regardless of the UGT1A1 genotypes. While no significant differences were found, grade >= 3 neutropenia and febrile neutropenia were more frequent in patients with UGT1A1*1/*6 or *1/*28 than in those with UGT1A1*1/*1 genotypes (grade >= 3 neutropenia, 50.0% vs. 30.8%, p = 0.24; febrile neutropenia, 9.1% vs. 0.0%, p = 0.20, respectively). No significant difference in progression-free survival (PFS) and overall survival (OS) was observed between irinotecan-naive-patients and other patients. However, irinotecan-resistant patients showed significantly shorter PFS (hazard ratio (HR) 2.83, p = 0.017) and OS (HR 2.58, p = 0.033) than other patients. Our study indicated that patients with UGT1A1*1/*6 or *1/*28 may be prone to neutropenia, though further study is needed. The survival benefit of nal-IRI+5-FU/LV could be maintained in patients without disease progression after irinotecan therapy.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.3390/jcm12041596